Attached Carole Ho - 23 Aug 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Chief Medical Officer
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
23 Aug 2023
Net transactions value
-$58,561
Form type
4
Filing time
25 Aug 2023, 17:30:21 UTC
Previous filing
23 Aug 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $58,561 -2,522 -1.4% $23.22 182,809 23 Aug 2023 See footnote F1, F2
holding DNLI Common Stock 25,000 23 Aug 2023 See footnote F3
holding DNLI Common Stock 109,124 23 Aug 2023 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2022.
F2 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F3 The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F4 Includes 108,714 RSUs.